Venetoclax in a patient with light chain deposition disease secondary to MGRS that progressed after kidney transplantation

Light chain deposition disease (LCDD) is commonly associated with monoclonal gammopathy of renal significance (MGRS). Venetoclax is a Bcl-2 inhibitor approved for the treatment of chronic lymphocytic leukemia with activity against multiple myeloma and AL amyloidosis clones that harbor the t(11;14) abnormality. Here, we report the first use of venetoclax in a patient with LCDD secondary to MGRS after kidney transplantation. A 43 year-old male presented with 17.9 g/d of proteinuria and creatinine of 3.7 mg/dl.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research